Exposure of airway smooth muscle (ASM) cells to the cytokine IL-1␤ results in an induction of PGE 2 synthesis that affects numerous cell functions. Current dogma posits induction of COX-2 protein as the critical, obligatory event in cytokine-induced PGE 2 production, although PGE 2 induction can be inhibited without a concomitant inhibition of COX-2. To explore other putative regulatory features we examined the role of phospholipase A 2 (PLA2) and PGE synthase (PGES) enzymes in IL-1␤-induced PGE 2 production. Treatment of human ASM cultures with IL-1␤ caused a time-dependent induction of both cytosolic PLA 2 (cPLA2) and microsomal PGES (mPGES) similar to that observed for COX-2. Regulation of COX-2 and mPGES induction was similar, being significantly reduced by inhibition of p42/p44 or p38, whereas cPLA 2 induction was only minimally reduced by inhibition of p38 or PKC. COX-2 and mPGES induction was subject to feed-forward regulation by PKA, whereas cPLA 2 induction was not. SB-202474, an SB-203580 analog lacking the ability to inhibit p38 but capable of inhibiting IL-1␤-induced PGE 2 production, was effective in inhibiting mPGES but not COX-2 or cPLA 2 induction. These data suggest that although COX-2, cPLA 2, and mPGES are all induced by IL-␤ in human ASM cells, regulatory features of cPLA 2 are dissociated, whereas those of COX-2 and mPGES are primarily associated, with regulation of PGE 2 production. mPGES induction and, possibly, cPLA 2 induction appear to cooperate with COX-2 to determine IL-1␤-mediated PGE 2 production in human ASM cells.
RECENT STUDIES HAVE REVEALED the pleiotropic nature of airway smooth muscle (ASM). Beyond its ability to contract and regulate airway patency, ASM works in concert with other airway cells in an immunomodulatory capacity (11, 21) . The resultant inflammatory milieu in turn exerts regulatory effects on ASM contractile state and synthetic functions.
The proinflammatory cytokine interleukin-1␤ (IL-1␤) activates numerous pathways in ASM capable of modulating multiple ASM functions (1) . One such pathway is that resulting in the production of autocrine PGE 2 synthesis. A large induction of PGE 2 synthesis in ASM elicited by chronic treatment with IL-1␤ or combined IL-1␤ and tumor necrosis factor-␣ (TNF-␣) results in profound inhibition of agonist-induced contraction and cell proliferation, promotes desensitization or sensitization of various G protein-coupled receptors, and has differential effects on cytokine synthesis (2, 9, 10, 15, 24 -26, 32) in multiple models of ASM function including primary cell cultures, ex vivo ASM strips, and in vivo models assessing pulmonary function [reviewed in Billington and Penn (4) ].
Studies examining regulatory features of cytokine-induced PGE 2 synthesis have posited induction of cyclooxygenase (COX)-2 protein as the critical, obligatory event in PGE 2 production and the functional consequences thereof. COX-2-dependent PGE 2 synthesis involves coordinated activation of phospholipase A 2 (secretory or cytosolic), which provides arachidonic acid substrate to COX-2 and prostaglandin E 2 synthases (PGES), which convert the COX-2 product PGH 2 into PGE 2 . In ASM, inhibition of either induction of COX-2 protein or COX-2 activity causes a profound reduction in cytokine-induced PGE 2 synthesis, demonstrating the essential role of COX-2 induction (2, 7, 13, 23, 25, 28, 31) . To what extent cytokine-induced alterations in either phospholipase A 2 (PLA 2 ) or PGES activities contribute toward induced PGE 2 levels is unclear, although the current dogma suggests that COX-2 activity is limiting in PGE 2 synthesis. In other cell systems induction of cytosolic PLA 2 (cPLA 2 ) or microsomal PGES (mPGES) by cytokines has been observed, although the relevance of such induction is unclear (6, 19, 29) .
In a previous analysis of cytokine-promoted COX-2 induction we observed discordance between regulation of COX-2 and PGE 2 induction (25) . These findings suggest that the activity of another element(s) in the pathway mediating PGE 2 synthesis might be regulated by cytokines and could be selectively inhibited as a means of inhibiting PGE 2 synthesis. Here we examine regulatory features of cPLA 2 , mPGES, COX-2, and PGE 2 induction by IL-1␤ in human ASM (HASM) cells. We find that like COX-2, cPLA 2 and mPGES are induced by IL-1␤ treatment of ASM and provide evidence that regulation of multiple elements contributes to cytokine-induced PGE 2 synthesis.
METHODS

Materials.
Arachidonic acid- [5,6,8,9,11,12,14,15- human anti-COX-1, and human anti-mPGES antibodies were purchased from Cayman Chemical (Ann Arbor, MI). Human anti-cPLA2 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). SB-203580, SB-202474, bisindolylmaleimide I (Bis I), and U0126 were purchased from Calbiochem (San Diego, CA). IL-1␤ and TNF-␣ were purchased from Roche (Indianapolis, IN). Solid-phase extraction cartridges were purchased from Agilent Technologies (Palo Alto, CA). Fluorescent antibodies were purchased from Rockland (Gilbersville, PA) or Molecular Probes (Eugene, OR). Odyssey blocking buffer and the Li-Cor imaging system were purchased from Li-Cor (Lincoln, NE). All other reagents were purchased from Sigma (St. Louis, MO) or from previously identified sources (20) .
HASM cell culture. HASM cultures were established as described by Panettieri et al. (22) from human tracheae obtained from lung transplant donors in accordance with procedures approved by the University of Pennsylvania Committee on Studies Involving Human Beings. Characterization of this cell line with regard to immunofluorescence of smooth muscle actin and agonist-induced changes in cytosolic calcium has been previously reported (22) . Cells of passages 2-5 were plated at a density of 1 ϫ 10 4 cells/cm 2 on the appropriate dishes or coverslips as described below in fetal bovine serum-supplemented medium (20) . Seven days later, we growth-arrested cells by washing them with phosphate-buffered saline (PBS) and refeeding them with serum-free Ham's F-12 medium for 48 h as described previously (20) .
Assay of PGE2 accumulation. HASM cultures growth-arrested for 48 h were treated with vehicle or indicated inhibitors for 30 min before being treated with either 20 IU/ml IL-1␤, 10 ng/ml TNF-␣, or both for 18 h. PGE 2 from the harvested culture media was purified using C-18 columns as described previously (12) and subsequently quantified with the Biotrak RIA kit as per the manufacturer's instructions.
Analysis of COX-1, COX-2, mPGES, cPGES, and cPLA 2 expression. HASM cultures were grown in six-well plates and treated as described for PGE2 assays. After 18 h of treatment with cytokines, the plates were placed on ice, the media were then aspirated from the well, the well was washed once with cold PBS, and 200 l of 1% sodium dodecyl sulfate (SDS) sample buffer (20) were applied directly to the well. Cell lysates were harvested by scraping, boiled for 5 min in 1% SDS sample buffer, and sonicated. Samples were electrophoresed on either a 4 -20% gradient SDS polyacrylamide gel (to observe mPGES) or 10% SDS polyacrylamide gel, transferred to nitrocellulose membranes, and subsequently analyzed by immunoblotting for COX-2 or COX-1 expression using a 1:1,000 dilution of primary antibody, for cPLA2 expression using a 1:500 dilution of primary antibody, for mPGES and cPGES antibodies using a 1:1,000 dilution of primary antibody, and either Alexa 688 or IRDye 800 secondary antibodies conjugated with infrared fluorophores. Bands were visualized and directly quantified with the Odyssey Infrared Imaging System (Li-Cor) and, where appropriate, normalized to the value obtained for the vehicle-treated condition or to the IL-1␤-treated condition when basal protein expression was undetectable.
cPLA2 activity assay. Assay of cPLA2 activity was performed as described previously (33) . In brief, cells were plated in 150-mm dishes and treated as described above. Cytosolic protein fractions were prepared in assay buffer: 100 mM KCl, 10 mM HEPES, 1 mM EDTA, and 1 mM EGTA containing 100 M leupeptin, 50 M pepstatin A, 2 mM sodium vanadate, and 10 mM diisopropyl fluorophosphates. The final assay mixture also contained 400 pM of sonicated micelles of 1-palmitoyl-2-[
14 C]arachidonyl-phosphatidylcholine, 5 mM CaCl2, 5 mM dithiothreitol (DTT), 200 g BSA, and 40 g of cytosolic protein in a final volume of 525 l and was warmed to 37°C in a shaking bath to initiate reactions. Reactions were stopped by solvent extraction; lipids were resolved by TLC, visualized, scraped, and counted by liquid scintillation. The percent hydrolysis was calculated as described in Ref. 33 . Generation of ASM cultures with stable expression of green fluorescent protein (GFP) or protein kinase A inhibitor (PKI)-GFP was as described in Guo et al. (8) .
Data presentation and statistical analysis. Data points from individual assays represent the mean values from duplicate or triplicate measurements. Statistical analysis of data was performed with GraphPad Prism (San Diego, CA) software. Except where noted, data are presented as means Ϯ SE. To minimize interexperimental variability in subsequent experiments that examined the effect of various inhibitory agents, group values were normalized to values for the IL-1␤-vehicle condition. Statistically significant differences among groups were assessed either by ANOVA with Fisher's post hoc analysis or by t-test for paired samples with P Ͻ 0.05 sufficient to reject the null hypothesis.
RESULTS
IL-1␤-mediated PGE 2 production in HASM is regulated by PKC, MAPKs, and corticosteroids.
Initial studies characterized regulatory features of IL-1␤-mediated PGE 2 production in HASM. In growth-arrested HASM cells, basal PGE 2 production over 18 h was low ( Fig. 1) . Consistent with our previous results (25), 18-h treatment with IL-1␤ resulted in a large (ϳ25-fold) induction of PGE 2 production over basal levels. Pretreatment with inhibitors of p42/p44 MAPK (U0126), p38 MAPK (SB-203580), or conventional PKC isoforms (Bis I) all significantly inhibited (ϳ70 -90%) this induction. Pretreatment with dexamethasone essentially eliminated IL-1␤-mediated PGE 2 production. Somewhat surprisingly, pretreatment with SB-202474, an analog of SB-203580 that lacks the ability to inhibit p38 (16) , also caused a profound inhibition of the induction of PGE 2 .
COX-2, cPLA 2 , and mPGES protein expression are induced by IL-1␤ and exhibit differential regulation. As previously demonstrated by our group and others chronic treatment with IL-1␤ resulted in a large induction of COX-2 protein expression in HASM, whereas levels of COX-1 were unchanged (Fig.  2) . Consistent with our analysis of the regulation of PGE 2 induction and the essential role of COX-2, pretreatment with U0126, SB-203580, or dexamethasone significantly inhibited IL-1␤-induced COX-2. Interestingly, neither SB-202474 nor Bis I, both effective in inhibiting IL-1␤-mediated PGE 2 production, had a significant effect on the induction of COX-2. This finding suggested a component/feature of the PGE 2 synthetic machinery whose regulation differs from that of COX-2 induction.
We therefore considered the contribution of altered PLA 2 and PGES activities to IL-1␤-mediated PGE 2 production. Examination of cPLA 2 protein expression following chronic IL-1␤ treatment revealed a significant (Ͼ4-fold) induction of cPLA 2 protein expression (Fig. 3) . Regulation of this induction was radically different from that observed for the induction of COX-2. Inhibition of p42/p44 had no effect on cPLA 2 induction. A small but significant inhibitory effect (ϳ25%) by Bis I and SB-203580 was observed. Pretreatment with SB-202474 had no significant effect, and dexamethasone pretreatment essentially eliminated cPLA 2 induction.
To determine whether the induction of cPLA 2 protein translated into an increase in cellular PLA 2 activity, we examined PLA 2 activity in both intact cells and cell-free assays. Interestingly, we found that IL-1␤ did not affect whole cell arachidonic acid release over the course of 18-h treatment (Fig. 4) . Although pretreatment with U0126 and Bis I inhibited arachidonic acid release in both vehicle (not shown)-and IL-1␤-treated cells, none of the other inhibitors affected arachidonic acid release. Because both secretory PLA 2 (sPLA 2 ) and cPLA 2 isoforms can contribute to cellular arachidonic acid release and because studies examining cPLA 2 knockout mice suggest that COX-dependent PGE 2 synthesis requires cPLA 2 (5), we examined the regulation of cPLA 2 in an in vitro assay. PLA 2 activity in cellular lysates (in which sPLA 2 activity was neutralized) was significantly increased by 18-h treatment of cells by IL-1␤ (Fig. 5) . Inhibition of p38 or PKC had a small but nonsignificant effect, whereas dexamethasone pretreatment significantly inhibited this induction of activity. Thus, unlike global PLA 2 activity (Fig. 4 ), which appears dominated by sPLA 2 activity, cPLA 2 enzymatic activity is induced and regulated in a manner similar to the observed induction of cPLA 2 protein.
As with both COX-2 and cPLA 2 , mPGES protein expression was upregulated (ϳ4-fold) by chronic IL-1␤ treatment (Fig. 6,  A and B) . Conversely, no change in cPGES expression after IL-1␤ pretreatment was observed (Fig. 6C) . The mPGES induction was sensitive to each of the inhibitory agents examined. Pretreatment with U0126 or SB-203580 significantly reduced (ϳ30 and 50%, respectively) the induction of mPGES, whereas dexamethasone eliminated it. Bis I pretreatment caused a small mPGES induction (Ӎ25%) that was not statistically significant (P ϭ 0.2). Regulation of mPGES induction was unique in that SB-202474 had a significant inhibitory effect, suggesting that inhibition of mPGES expression/activity could contribute to the inhibitory effect of SB-202474 on IL-1␤-mediated PGE 2 production.
PKA differentially regulates COX-2, cPLA 2 , and mPGES. We have recently established that PKA participates in a feedforward mechanism that augments IL-1␤-induced COX-2 and PGE 2 synthesis in HASM (8) . To examine the regulatory role of PKA in the induction of cPLA 2 and mPGES, HASM cells selected for stable expression of GFP or a GFP chimera of the PKA inhibitory peptide PKI (PKI-GFP) [characterized in Guo et al. (8) ] were treated 18 h with vehicle, IL-1␤, or IL-1␤ ϩ TNF-␣, and protein expression of COX-2, cPLA 2 , and mPGES was assessed. As previously shown, the induction of COX-2 was mitigated in cells expressing PKI-GFP, and this was associated with a reduction in PGE 2 production (Fig. 7, A, B,  E) . Conversely, the induction of cPLA 2 was minimally affected by expression of PKI-GFP (Fig. 7, A and D) , suggesting that regulation of cPLA 2 gene transcription is not PKA dependent and unaffected by autocrine PGE 2 production. As with COX-2, induction of mPGES was reduced (ϳ35%) in lines expressing PKI-GFP (Fig. 7, A and C) , suggesting that mPGES upregulation is similarly subject to feed-forward regulation mediated by PGE 2 production and associated PKA activation.
Collectively, these data suggest that although COX-2, cPLA 2 , and mPGES are all induced by IL-1␤ in HASM cells, regulatory features of cPLA 2 are dissociated, whereas those of COX-2 and mPGES are primarily associated, with regulation of PGE 2 production. Differential regulation of COX-2 and mPGES induction may explain the role of PKC, and possibly the effects of SB-202474 on IL-1␤-induced PGE 2 , and suggests a role for mPGES induction in promoting the full effect of IL-1␤ on autocrine PGE 2 production.
DISCUSSION
The present study demonstrates that in human ASM, IL-1␤-mediated cPLA 2 , COX-2, and mPGES protein induction are regulated by distinct mechanisms. Whereas IL-1␤ effects the coordinate induction of all three enzymes, albeit to different extents, the profile of signaling pathways mediating the induction of each enzyme is distinct. These findings represent the first report of cytokine-mediated induction of cPLA 2 protein expression and enzymatic activity in ASM. Novel mechanistic insight is also provided by demonstration that regulation of IL-1␤-mediated cPLA 2 induction differs from that for COX-2 or mPGES. IL-1␤-mediated cPLA 2 induction was abrogated by steroid pretreatment, modestly sensitive to PKC and p38 MAPK inhibition, but resistant to the inhibition of p42/p44 MAPK or PKA. In contrast, IL-1␤-mediated COX-2 induction was highly sensitive to p42/p44 MAPK, PKA, and p38 inhibition, whereas PKC inhibition had a minimal effect. Similar to what has been reported previously in ASM, IL-1␤-mediated COX-2 induction was highly sensitive to steroid pretreatment (3, 24, 32 ).
Also we demonstrate for the first time a cytokine-mediated induction of mPGES protein expression in ASM. Interestingly, IL-1␤-mediated mPGES induction was sensitive to inhibition of all of the pathways tested including p38, p42/p44, PKA, and classical PKC; however, the inhibition in each case was only modest. Thus the profile of signaling pathways regulating IL-1␤-mediated mPGES induction was qualitatively similar to that of COX-2. However, in contrast to what was observed for cPLA 2 and COX-2, IL-1␤-mediated mPGES induction was sensitive to pretreatment with the imidazole compound SB-202474. This finding may explain, in part, the observed effect of SB-202474 on IL-1␤-mediated PGE 2 production. Notably this finding suggests that induction of mPGES contributes significantly to the observed PGE 2 production.
Clearly the regulation of IL-1␤-mediated PGE 2 production in human ASM is a complex process. Existing dogma holds that IL-1␤-mediated COX-2 induction in ASM is the key regulatory step that ultimately determines PGE 2 production. Previous analyses of the regulatory features of IL-1␤-mediated PGE 2 production in ASM have focused on the role of COX-2 induction (3, 7, 15, 23, 24, 31) . Studies in other cell types have suggested but have not directly shown that PLA 2 is upregulated by IL-1␤ treatment. Saunders et al. (27) reported that in A549 pulmonary epithelial cells IL-1␤ treatment for 24 h mediated COX-2 induction but that the subsequent rate of PGE 2 release was very low. Treatment of the IL-1␤-primed cells with bradykinin or the calcium ionophore A-23187 resulted in large increases in PGE 2 production. The authors proposed that IL-1␤-mediated PLA 2 was stimulated by these agents to release arachidonic acid that was subsequently utilized by COX-2/ mPGES to make PGE 2 . Newton et al. (18) , also using A549 cells, demonstrated that inhibition of p38 and p42/p44 resulted in minimal inhibition of IL-1␤-mediated COX-2 induction but a disproportionate reduction in PGE 2 production. Because p38 and p42/p44 inhibition also diminished IL-1␤-mediated arachidonic acid release, they asserted a key role for PLA 2 -mediated arachidonic acid release in subsequent PGE 2 production. This group had also previously shown that in A549 cells IL-1␤ treatment resulted in the upregulation of cPLA 2 mRNA and that this effect was steroid sensitive (19) . These results cannot be generalized to ASM because p38 and p42/p44 signaling appears to be required for maximal IL-1␤-mediated COX-2 induction in ASM (13, 14, 25) but plays a minor role in A549 cells.
Clarifying the regulation of PLA 2 and PGES enzymes and their role in PGE 2 generation in ASM. There are a large number of phospholipases that are capable of releasing arachidonic acid from membrane phospholipid and hence potentially capable of contributing to PGE 2 generation in ASM. Indeed the fact that IL-1␤ does not change overall arachidonic acid release (Fig. 4) , even though cPLA 2 expression is clearly increased, suggests that other phospholipase activity exists that does not necessarily contribute to the observed induction of PGE 2 . That in vitro PLA 2 activity increases proportionately with cPLA 2 expression and because this assay is performed in the presence of DTT (a potent inhibitor of sPLA 2 enzymatic activity) supports the notion that IL-1␤-mediated PLA 2 activity is due to cPLA 2 and not sPLA 2 . Most studies to date that have examined PLA 2 -COX enzyme coupling suggest that cPLA 2 is the PLA 2 that is functionally coupled to COX-2 (17) . Indeed, the targeted deletion of cPLA 2 in mice results in an animal that is not capable of producing PGE 2 in response to cytokine stimulation (5, 30) . We examined the effect of IL-1␤ treatment on the constitutively expressed cPGES and found that cPGES is constitutively expressed and not regulated by IL-1␤. This result suggests that cPGES does not contribute in a substantial way towards IL-1␤-mediated PGE 2 production.
We previously examined IL-1␤-mediated COX-2 induction and PGE 2 production in HASM and identified conditions under which regulation of PGE 2 induction appears dissociated from the regulation of COX-2 induction (25) . For example, the imidazole SB-202474 reduced IL-1␤-mediated PGE 2 production by Ͼ80%, whereas its effect on IL-1␤-mediated COX-2 induction was minimal. Similarly, MEK1/2 inhibitor U0126 abrogated PGE 2 generation even though its inhibition of IL-1␤-mediated COX-2 induction was considerably less. Moreover, cotreatment of human ASM with IL-1␤ ϩ TNF-␣ or IL-1␤ ϩ EGF resulted in an additive effect on COX-2 induction but more than additive increases in PGE 2 production. Interestingly, COX-2 induction under these conditions was resistant to the inhibition of p38 or p42/p44 even though the inhibition of PGE 2 remained nearly complete. These results strongly suggested that the regulation of cytokine-mediated PGE 2 production was not totally dependent on the level of COX-2 but that other regulatory elements were involved.
To gain an appreciation of which regulatory elements may be involved we first examined the role of cPLA 2 in IL-1␤-mediated PGE 2 production. This isoform of PLA 2 was chosen because although several PLA 2 enzymes can release arachidonic acid from membrane phospholipids, the central role of cPLA 2 in prostanoid production has been established by its targeted deletion in mice (5, 30) . Moreover, cotransfection studies have suggested that cPLA 2 preferentially couples to COX-2 with resultant prostanoid production (17) . In HASM we observe that cPLA 2 is constitutively expressed under basal conditions, and somewhat surprisingly we observed that chronic IL-1␤ treatment resulted in a robust three-to fourfold induction of both cPLA 2 expression and in vitro PLA 2 activity. Interestingly, IL-1␤-mediated cPLA 2 expression was not regulated by p42/p44 but was modestly sensitive to p38 and PKC inhibition. Thus the differential effects on PGE 2 production and COX-2 expression by p38 and PKC can be explained in part by IL-1␤-mediated regulation of cPLA 2 . However, the effects of p38 and PKC inhibition on cPLA 2 expression are only modest, and p42/p44 inhibition has no effect on IL-1␤-mediated cPLA 2 expression. Interestingly, none of the inhibitors tested had any effect on IL-1␤-mediated PLA 2 activity in vitro. However, because of the repertoire of PLA 2 enzymes that can release arachidonic acid in vitro, it is likely that we cannot discriminate the regulation of cPLA 2 using an in vitro assay.
We next turned our attention to the study of IL-1␤-mediated mPGES. This enzyme was of interest because several studies in different cell systems have demonstrated that IL-1␤ mediates the coordinate induction of COX-2 and mPGES (6, 29) . Consistent with these studies, we found that mPGES was also induced by IL-1␤ in ASM cells and that under most conditions in which COX-2 induction was inhibited, mPGES induction was similarly inhibited. The notable exception was the significant inhibitory effect of SB-202474 on mPGES induction only. Because SB-202474 also significantly inhibits IL-1␤-mediated PGE 2 induction, these results implicate the induction of mPGES as an important contribution to the induction of PGE 2 by IL-1␤.
Because we had previously determined that COX-2 induction by both IL-1␤ and combined IL-1␤ and TNF-␣ treatment was augmented in a feed-forward manner by the PKA activity associated with COX-2/PGE 2 induction, we examined whether PKA similarly regulates the induction of cPLA 2 and mPGES. As previously demonstrated (8), PKI-GFP inhibited cytokineinduced PKA activity as evidenced by inhibition of PKAmediated phosphorylation of the intracellular PKA substrate vasodilator-associated phosphoprotein, and this was associated with a reduction in cytokine-induced PGE 2 production (Fig. 7,  A and E) . Interestingly, we again observed that regulation of mPGES induction was similar to that of COX-2, with cells expressing a PKI inhibitory peptide exhibiting a significantly lesser induction of both COX-2 and mPGES in response to cytokine treatment (Fig. 7, B and C) . However, induction of cPLA 2 was not affected by PKA inhibition (Fig. 7D) , demonstrating another instance in which the regulation of this enzyme was distinct from that of COX-2 and mPGES.
In summary, the present study details the regulatory features of IL-␤-mediated COX-2, cPLA 2 , and mPGES induction in ASM cells and relates these features to the regulation of PGE 2 induction. Future studies emphasizing imaging of subcellular compartmentalization of the induced enzymes will likely enhance our understanding of how the activity of these enzymes is coordinated to promote PGE 2 synthesis.
